Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 1011-1015

  Capeller, Barbara ^a   Caffier, H ^a   Sutterlin M W ^a   Dietl, J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Bone metastases; Breast cancer; Prognostic factor; Tartrate resistant acid phosphatase; Tumor marker

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; PHOSPHONIC ACID DERIVATIVE; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CARCINOMA; CANCER GROWTH; CANCER PATIENT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; ENZYME SPECIFICITY; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; SERUM;

ACID PHOSPHATASE; ADULT; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; ISOENZYMES; MIDDLE AGED; NEOPLASM METASTASIS; POSTMENOPAUSE; PREMENOPAUSE; REFERENCE VALUES; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0037861873     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Pavlakis N and Stockler M: Bisphosphonates in breast cancer (Cochrane Review). Cochrane Database Syst Rev 1, 2002.
2. Solomayer EF, Diel IJ, Meyberg GC, Gollan C and Bastert G: Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59: 271-8, 2000.
3. Diel IJ, Solomayer EF and Bastert G: Bisphosphonates and the prevention of metastasis first evidences from preclinical and clinical studies. Cancer 88: 3080-8, 2000.
4. Coleman RE, Smith P and Rubens RD: Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 77: 336-40, 1998.
5. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ and Vaananen HK: Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15: 1337-45, 2000.
6. Lam KW, Li CY, Yam LT and Desnick RJ: Comparison of the tartrate-resistant acid phosphatase in Gaucher's disease and leukemic reticuloendothellosis. Clin Biochem 14: 177-81, 1981.
7. Janckila AJ, Takahashi K, Sun SZ and Yam LT: Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 47:74-80, 2001.
8. Halleen JM and Ranta R: Tartrate-resistant acid phosphatase as a serum marker of bone resorption. Am Clin Lab 20: 29-30, 2001.
9. Halleen J, Hentunen TA, Hellman J and Vaananen HK: Tartrate-resistant acid phosphatase from human bone: purification and development of an immunoassay. J Bone Miner Res 11: 1444-52, 1996.
10. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ and Vaananen HK: Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47: 597-600, 2001.
11. Galasko CS: Incidence and distribution of skeletal metastases. In: Bone Metastases (Galasko CS, ed) London: Butterworth; 1986, pp 14-21.
12. Yaziji H, Janckila AJ, Lear SC, Martin AW and Yam LT: Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoietic human tissues. Am J Clin Pathol 104: 397-402, 1995.
13. Price CP, Kirwan A and Vader C: Tartrate-resistant acid phosphatase as a marker of bone resorption. Clin Chem 41: 641-3, 1995.
14. Lau KH, Onishi T, Wergedal JE, Singer FR and Baylink DJ: Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem 33: 458-62, 1987.
15. Scarnecchia L, Minisola S, Pacitti MT, Carnevale V, Romagnoli E, Rosso R et al: Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 51: 517-24, 1991.
16. Cheung CK, Panesar NS, Haines C, Masarei J and Swaminathan R: Immunoassay of a tartrate-resistant acid phosphatase in serum. Clin Chem 41: 679-86, 1995.
17. Halleen JM, Hentunen TA, Karp M, Kakonen SM, Pettersson K and Vaananen HK: Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J Bone Miner Res 13: 683-7, 1998.
18. Halleen JM, Karp M, Viloma S, Laaksonen P, Hellman J, Kakonen SK et al: Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies. J Bone Miner Res 14: 464-9, 1999.
19. Body JJ, Coleman RE and Piccart M: Use of bisphosphonates in cancer patients. Cancer Treat Rev 22: 265-87, 1996.
20. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H et al: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16: 3890-9, 1998.
21. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-63, 1998.
22. Mardiak J, Bohunicky L, Chovanec J, Salek T and Koza I: Adjuvant clodronate therapy in patients with locally advanced breast cancer-long term results of a double blind randomized trial. Slovak Clodronate Collaborative Group. Neoplasma 47: 177-80, 2000.
23. Saarto T, Blomqvist C, Virkkunen P and Elomaa II: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Onc 19: 10-17, 2001.